NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $71.11
  • Forecasted Upside: 54.49 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$46.03
▼ -2.04 (-4.24%)
1 month | 3 months | 12 months
Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$71.11
▲ +54.49% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $71.11, with a high forecast of $91.00 and a low forecast of $49.00. The average price target represents a 54.49% upside from the last price of $46.03.
Buy
The current consensus among 9 investment analysts is to buy stock in Deciphera Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/5/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/3/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
1/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/2/2020Stifel NicolausInitiated CoverageBuy$75.00Medium
i
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$58.00 ➝ $70.00Low
i
9/14/2020SVB LeerinkBoost Price TargetMarket Perform$54.00 ➝ $58.00Medium
i
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
i
8/5/2020SVB LeerinkLower Price TargetMarket Perform$55.00 ➝ $54.00Low
i
6/12/2020GuggenheimReiterated RatingBuy$70.00High
i
5/18/2020SunTrust BanksBoost Price TargetBuy$82.00 ➝ $91.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/18/2020BarclaysReiterated RatingBuy$80.00 ➝ $85.00Medium
i
5/7/2020Nomura InstinetDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
i
5/6/2020NomuraDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
i
5/6/2020JPMorgan Chase & Co.Lower Price TargetOverweight$50.00 ➝ $49.00High
i
5/6/2020HC WainwrightBoost Price TargetBuy$60.00 ➝ $80.00High
i
4/29/2020SunTrust BanksBoost Price TargetBuy$77.00 ➝ $82.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
4/29/2020SVB LeerinkBoost Price TargetHold$50.00 ➝ $55.00Medium
i
3/4/2020BarclaysInitiated CoverageOverweight$70.00High
i
1/22/2020Piper SandlerReiterated RatingBuy$75.00Low
i
Rating by Christopher Raymond at Piper Sandler
1/21/2020Nomura SecuritiesBoost Price TargetBuy$57.00 ➝ $84.00Low
i
1/15/2020JMP SecuritiesReiterated RatingBuy$70.00Low
i
Rating by Reni Benjamin at JMP Securities
1/10/2020SunTrust BanksInitiated CoverageBuy$77.00Low
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
12/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$55.00 ➝ $75.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
12/20/2019Jefferies Financial GroupBoost Price TargetBuy$53.00 ➝ $77.00Medium
i
Rating by Eun Yang at Jefferies Financial Group Inc.
11/5/2019JMP SecuritiesBoost Price TargetOutperform ➝ Market Outperform$45.00 ➝ $54.00Low
i
10/29/2019SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00 ➝ $34.00Medium
i
Rating by A. Berens at SVB Leerink LLC
10/22/2019JMP SecuritiesInitiated CoverageOutperformLow
i
10/3/2019HC WainwrightInitiated CoverageBuy$60.00High
i
Rating by A. Fein at HC Wainwright
9/30/2019Piper Jaffray CompaniesSet Price TargetBuy$55.00High
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/30/2019Jefferies Financial GroupInitiated CoverageBuy$47.00High
i
8/14/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$60.00Low
i
8/14/2019SVB LeerinkReiterated RatingUnderperform ➝ Positive$20.00 ➝ $29.00High
i
8/14/2019Cantor FitzgeraldBoost Price TargetOverweight$43.00 ➝ $55.00High
i
8/14/2019Canaccord GenuityReiterated RatingBuy ➝ Buy$50.00 ➝ $65.00Medium
i
8/13/2019GuggenheimBoost Price TargetBuy$44.00 ➝ $66.00High
i
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$42.00Low
i
6/3/2019Piper Jaffray CompaniesBoost Price TargetOverweight$50.00 ➝ $55.00High
i
3/15/2019Canaccord GenuityLower Price TargetBuy ➝ Buy$55.00 ➝ $50.00High
i
1/1/2019B. RileyDowngradeBuy ➝ NeutralHigh
i
12/31/2018B. RileyInitiated CoverageNeutral ➝ Buy$27.00 ➝ $34.00High
i
Rating by G. Zavoico at B. Riley
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
11/16/2018SVB LeerinkLower Price TargetUnderperform$28.00 ➝ $20.00Medium
i
Rating by A. Berens at SVB Leerink LLC
10/3/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
9/24/2018SVB LeerinkInitiated CoverageUnderperform ➝ Underperform$28.00Low
i
Rating by A. Berens at SVB Leerink LLC
9/17/2018GuggenheimInitiated CoverageBuyHigh
i
9/6/2018Cantor FitzgeraldInitiated CoverageBuy$53.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
8/29/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$47.00Medium
i
8/22/2018Cantor FitzgeraldInitiated CoverageOverweight$53.00Medium
i
Rating by C. Duncan at Cantor Fitzgerald
8/13/2018Canaccord GenuitySet Price TargetBuy$55.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
8/7/2018Canaccord GenuityInitiated CoverageBuy$55.00Low
i
7/5/2018SunTrust BanksInitiated CoverageBuyHigh
i
6/19/2018JMP SecuritiesBoost Price TargetOutperform$65.00Low
i
6/19/2018B. RileyDowngradeBuy ➝ Neutral$43.00Medium
i
Rating by M. Kumar at B. Riley
6/12/2018Piper Jaffray CompaniesBoost Price TargetOverweight$50.00Low
i
6/4/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00High
i
5/9/2018B. RileyLower Price TargetBuy ➝ Buy$52.00 ➝ $43.00High
i
Rating by M. Kumar at B. Riley
2/16/2018B. RileyInitiated CoverageBuy ➝ Buy$43.00High
i
Rating by M. Kumar at B. Riley
10/23/2017Nomura SecuritiesInitiated CoverageBuy ➝ Buy$57.00N/A
i
10/23/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$35.00N/A
i
10/23/2017Nomura InstinetInitiated CoverageBuy$57.00N/A
i
10/23/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$38.00N/A
i
10/23/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$30.00N/A
i
(Data available from 1/27/2016 forward)
Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $46.03
$45.77
$48.20

50 Day Range

MA: $54.48
$46.76
$61.08

52 Week Range

Now: $46.03
$33.10
$71.11

Volume

398,791 shs

Average Volume

410,381 shs

Market Capitalization

$2.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Nomura, Nomura Instinet, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, and Zacks Investment Research.

What is the current price target for Deciphera Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $71.11, suggesting a possible upside of 54.5%. SunTrust Banks, Inc. has the highest price target set, predicting DCPH will reach $91.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $49.00 for Deciphera Pharmaceuticals in the next year.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCPH will outperform the market and that investors should add to their positions of Deciphera Pharmaceuticals.

What other companies compete with Deciphera Pharmaceuticals?

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is 781-209-6400 and its investor relations email address is [email protected] The official website for Deciphera Pharmaceuticals is www.deciphera.com.